Skip to main content

Table 4 Clinical associations of T&CM use

From: Clinical associations for traditional and complementary medicine use among Norwegian cancer survivors in the seventh survey of the Tromsø study: a cross-sectional study

 

Female, n = 655

Male, n = 652

 

T&CM, n = 242

%

No T&CM, n = 413

%

p-value

T&CM

n = 166

%

No T&CM n = 486

%

p-value

Self-reported health

    

0.038

    

0.341

Medium to good

217

88.8

386

93.5

 

157

94.6

449

92.4

 

Poor

27

11.2

27

6.5

 

9

5.4

37

7.6

 

Cancer site first diagnosis

    

0.876

    

0.954

Breast

98

40.5

164

39.7

 

-

 

-

  

Female genital organs

32

13.2

73

17.7

 

-

 

-

  

Prostate

-

 

-

  

74

44.6

212

43.6

 

Other male genital organs

-

 

-

  

14

8.4

35

7.2

 

Respiratory organs

7

2.9

11

2.7

 

2

1.2

11

2.3

 

Melanoma and skin

24

9.9

36

8.7

 

18

10.8

49

10.1

 

Colon

16

6.6

31

7.5

 

13

7.8

39

8.0

 

Other digestive organs

12

5.0

19

4.6

 

11

6.6

30

6.2

 

Hematologic*

14

5.8

23

5.6

 

11

6.6

45

9.3

 

Other cancers

39

16.1

56

13.6

 

23

13.9

65

13.4

 

Breast cancer

    

0.843

     

Breast

98

40.5

144

39.7

      

Other sites

144

59.5

249

60.3

      

Prostate cancer

         

0.830

Prostate

     

74

44.6

212

43.6

 

Other sites

     

92

55.4

274

56.1

 

Metastasis at first diagnosis

    

0.254

    

0.680

Metastasis

71

34.1

104

30.1

 

38

27.5

121

30.4

 

No metastasis

136

65.4

242

69.9

 

100

72.5

276

69.3

 

Unknown

1

0.5

0

0.0

 

0

0.0

1

0.3

 

Time since first cancer diagnosis

    

0.002

    

0.703

less than a year

21

8.7

29

7.0

 

17

10.2

50

10.3

 

1–5 years

100

41.3

118

28.6

 

67

40.4

200

41.2

 

6–10 years

48

19.8

87

21.1

 

38

22.9

92

18.9

 

more than 10 years

73

30.2

179

43.3

 

44

26.5

144

29.6

 

Number of cancer diagnoses

    

0.132

    

0.303

Cancer once

209

86.4

338

81.8

 

137

82.5

383

78.8

 

Cancer twice or more times

33

13.6

75

18.2

 

29

17.5

103

21.2

 

Only one treatment modality

    

0.372

    

.5591

Surgery

28

27.2

45

31.3

 

26

55.3

85

55.6

 

CT

12

11.7

18

12.5

 

7

14.9

20

13.1

 

RT

60

58.3

71

49.3

 

11

23.4

44

28.8

 

HT

3

2.9

10

6.9

 

3

6.4

4

2.6

 

Multimodal treatment

          

Surgery and CT

58

24.0

121

29.3

0.140

49

29.5

144

29.6

0.978

Surgery and RT

112

46.3

189

45.8

0.898

53

31.9

169

34.8

0.503

Surgery and HT

38

15.7

101

24.5

0.008

32

19.3

103

21.1

0.599

CT and RT

51

21.1

93

22.5

0.667

16

9.6

71

14.6

0.104

CT and HT

43

17.8

75

18.2

0.900

15

9.0

60

12.3

0.249

Surgery, CT and HT

59

24.4

113

27.4

0.403

34

20.5

116

23.9

0.371

CT, HT and RT

52

21.5

94

22.8

0.706

17

10.2

73

15.0

0.123

Surgery, HT and RT

41

16.9

106

25.7

0.010

34

20.5

112

23.0

0.494

Surgery, CT and RT

61

25.2

119

28.8

0.318

34

20.5

122

251

0.228

Surgery, CT, RT and HT

61

25.2

119

28.8

0.318

35

21.1

122

25.1

0.296

  1. T&CM: Traditional and Complementary Medicine. *Hematologic = Lymphoid, hematopoietic, and related tissue. 1Fisher-Freeman-Halton Exact Test. CT: Chemotherapy; RT: Radiotherapy; HT: Hormone therapy